These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 38728099

  • 1. Cytomegalovirus surveillance after antiviral prophylaxis in CMV mismatched transplant patients: Does recurrent cytomegalovirus DNAemia impact patient survival?
    Fernández-García OA, Hernandez C, Robbins M, Kabbani D, Doucette K, Cervera C.
    Transpl Infect Dis; 2024 Aug; 26(4):e14292. PubMed ID: 38728099
    [Abstract] [Full Text] [Related]

  • 2. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 3. Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
    Solano C, Giménez E, Piñana JL, Albert E, Vinuesa V, Hernández-Boluda JC, Amat P, Navarro D.
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28471073
    [Abstract] [Full Text] [Related]

  • 4. Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients.
    Ganapathi L, Blumenthal J, Alawdah L, Lewis L, Gilarde J, Jones S, Milliren C, Kim HB, Sharma TS.
    Pediatr Transplant; 2019 Nov; 23(7):e13568. PubMed ID: 31515909
    [Abstract] [Full Text] [Related]

  • 5. The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients.
    Gardiner BJ, Chow JK, Brilleman SL, Peleg AY, Snydman DR.
    Transpl Infect Dis; 2019 Dec; 21(6):e13189. PubMed ID: 31581352
    [Abstract] [Full Text] [Related]

  • 6. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
    Vinuesa V, Bracho MA, Albert E, Solano C, Torres-Puente M, Giménez E, González-Candelas F, Navarro D.
    J Gen Virol; 2017 Oct; 98(10):2530-2542. PubMed ID: 28874227
    [Abstract] [Full Text] [Related]

  • 7. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.
    Talaya A, Giménez E, Piñana JL, Albert E, Hernández-Boluda JC, Pérez A, Torres I, Solano C, Navarro D.
    J Med Virol; 2019 Jun; 91(6):1128-1135. PubMed ID: 30735250
    [Abstract] [Full Text] [Related]

  • 8. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
    Huntley D, Giménez E, Pascual MJ, Hernández-Boluda JC, Gago B, Vázquez L, Piñana JL, García M, Pérez A, Serrano D, Hernández M, Albert E, Solano C, Navarro D.
    Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
    [Abstract] [Full Text] [Related]

  • 9. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [Abstract] [Full Text] [Related]

  • 10. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 11. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S.
    Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
    [Abstract] [Full Text] [Related]

  • 12. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF, Anderson AD, Rosa R, Kimble E, Komanduri KV, Morris MI.
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [Abstract] [Full Text] [Related]

  • 13. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB, Phadke VK, Pouch SM, Mehta AK, Karadkhele G, Larsen CP, Woodworth MH.
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [Abstract] [Full Text] [Related]

  • 14. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, Mao C, Garro R, Yildirim I.
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [Abstract] [Full Text] [Related]

  • 15. Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients.
    Natori Y, Alghamdi A, Husain S, Rotstein C, Selzner N, Tikkanen J, Schiff J, Humar A, Kumar D.
    Transpl Infect Dis; 2020 Feb; 22(1):e13207. PubMed ID: 31677321
    [Abstract] [Full Text] [Related]

  • 16. CMV infection and management among pediatric solid organ transplant recipients.
    Downes KJ, Sharova A, Boge CLK, Vader D, Mitrou M, Hayes M, Galetaki DM, Gianchetti L, Vella LA, Li Y.
    Pediatr Transplant; 2022 May; 26(3):e14220. PubMed ID: 34994041
    [Abstract] [Full Text] [Related]

  • 17. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB, Pouch SM, Phadke VK, Karadkhele G, Larsen CP, Woodworth MH.
    Transpl Infect Dis; 2024 Feb; 26(1):e14219. PubMed ID: 38158932
    [Abstract] [Full Text] [Related]

  • 18. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
    Muñoz-Cobo B, Solano C, Costa E, Bravo D, Clari MÁ, Benet I, Remigia MJ, Montoro J, Navarro D.
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
    [Abstract] [Full Text] [Related]

  • 19. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
    Lisboa LF, Preiksaitis JK, Humar A, Kumar D.
    Transplantation; 2011 Nov 15; 92(9):1063-8. PubMed ID: 21878838
    [Abstract] [Full Text] [Related]

  • 20. Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies.
    Huntley D, Talaya A, Giménez E, Martínez A, Hernández-Boluda JC, Hernani R, Torres I, Alberola J, Albert E, Piñana JL, Solano C, Navarro D.
    Biol Blood Marrow Transplant; 2020 May 15; 26(5):972-977. PubMed ID: 32007638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.